Cara Therapeutics Inc (CARA)
0.715
-0.02
(-2.88%)
USD |
NASDAQ |
Apr 23, 09:35
Cara Therapeutics Revenue (Quarterly): 3.004M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.004M |
| September 30, 2023 | 4.866M |
| June 30, 2023 | 6.933M |
| March 31, 2023 | 6.165M |
| December 31, 2022 | 3.261M |
| September 30, 2022 | 10.81M |
| June 30, 2022 | 23.00M |
| March 31, 2022 | 4.79M |
| December 31, 2021 | 0.821M |
| September 30, 2021 | 20.27M |
| June 30, 2021 | |
| March 31, 2021 | 1.935M |
| December 31, 2020 | 112.09M |
| September 30, 2020 | 9.266M |
| June 30, 2020 | 5.634M |
| March 31, 2020 | 8.093M |
| December 31, 2019 | 4.511M |
| September 30, 2019 | 5.785M |
| June 30, 2019 | 5.208M |
| March 31, 2019 | 4.382M |
| December 31, 2018 | 5.533M |
| September 30, 2018 | 5.062M |
| Date | Value |
|---|---|
| June 30, 2018 | 2.874M |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | 0.911M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | 0.079M |
| March 31, 2016 | 0.007M |
| December 31, 2015 | |
| September 30, 2015 | 2.44M |
| June 30, 2015 | 0.874M |
| March 31, 2015 | 0.489M |
| December 31, 2014 | 0.914M |
| September 30, 2014 | 1.125M |
| June 30, 2014 | 0.96M |
| March 31, 2014 | 0.178M |
| December 31, 2013 | 0.973M |
| September 30, 2013 | 1.018M |
| June 30, 2013 | 9.973M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.821M
Minimum
Dec 2021
112.09M
Maximum
Dec 2020
13.14M
Average
5.710M
Median
Revenue (Quarterly) Benchmarks
| Nektar Therapeutics | 23.88M |
| Stereotaxis Inc | 4.565M |
| Cerus Corp | 46.77M |
| Avid Bioservices Inc | 25.40M |
| Rigel Pharmaceuticals Inc | 35.79M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -32.34M |
| Total Expenses (Quarterly) | 35.61M |
| EPS Diluted (Quarterly) | -0.60 |
| Enterprise Value | -60.52M |
| Gross Profit Margin (Quarterly) | 79.76% |
| Profit Margin (Quarterly) | -1.08K% |
| Earnings Yield | -306.3% |
| Normalized Earnings Yield | -306.29 |